FDA Brief

Warning letters Drugs

FDA warning letter to

Soliteint Kozmetikai KFT

High riskIssued Oct 10, 2024Posted Oct 22, 2024Center for Drug Evaluation and Research (CDER)

Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

What happened

FDA inspected the Fot, Hungary facility from April 15 to 19, 2024. Investigators found the company released over-the-counter topical pain-relief drugs without testing them for identity and strength of active ingredients, and used menthol and other ingredients without testing incoming lots itself, relying on supplier certificates instead. FDA also found water system problems, no process validation, and a quality unit without basic procedures; the company told FDA it has stopped making OTC drugs for the U.S. market.

What FDA found

  1. The company released drug batches without testing them to confirm the identity and strength of each active ingredient, and without testing for harmful microorganisms.

    21 CFR 211.165(a) and 211.165(b)
  2. The company did not test incoming ingredients to confirm identity and did not verify the reliability of its suppliers' test results; its last supplier assessment was in March 2001.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. Because of problems with its water treatment system, the company used water as a drug ingredient without data showing how often the water was tested for organic carbon or microbes such as Burkholderia cepacia.

  4. The company did not test each lot of glycerin for diethylene glycol or ethylene glycol, impurities that have caused fatal poisonings worldwide.

  5. The company did not perform process validation for the OTC drugs it made for the U.S. market.

    21 CFR 211.100(a)
  6. The quality control unit lacked procedures for corrective and preventive actions, quality status labeling, and master batch records, and stability testing did not support the assigned expiration dates.

    21 CFR 211.22

What FDA wants

FDA asks the company to reply in writing within 15 working days describing corrections and preventive actions, with detailed plans for laboratory testing, supplier and water system controls, process validation and quality unit oversight. The company must also send diethylene glycol and ethylene glycol test results within 30 calendar days and notify FDA before resuming any drug manufacturing for the U.S. market.

Who should pay attention

  • brands that hire this site as a contract manufacturer of U.S. OTC topical drugs
  • U.S. distributors and retailers selling Asutra and other cited OTC analgesics
  • companies buying glycerin-based topical products or ingredients from this supplier network

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk